Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results
15 mars 2021 06h30 HE
|
Beam Therapeutics
Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing Team...
Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer
15 mars 2021 06h15 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference
04 mars 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Acquisition of Guide Therapeutics
23 févr. 2021 08h34 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced it has...
Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors
19 janv. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today...
Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors
11 janv. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
05 janv. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020
05 déc. 2020 07h00 HE
|
Beam Therapeutics
BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second Half of 2021 In Vivo Data from Makassar Base Editing Program...
The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020
20 nov. 2020 16h01 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today has been named...
Beam Therapeutics Presents First Data Highlighting Base Editing Program for Glycogen Storage Disease Type Ia at AASLD
13 nov. 2020 08h00 HE
|
Beam Therapeutics
Novel Base Editors for Two Most Common GSDIa Mutations Demonstrate Significantly Higher Levels of In Vivo Mutation Correction than Required to Restore Glucose Homeostasis Previously Presented Data...